Search

Background. Encapsulating peritoneal sclerosis (EPS) is a severe complication of long-term peritoneal dialysis (PD) characterized by the development of an extensive fibrosis of the visceral peritoneum that may eventually lead to intestinal constriction. Its cause remains elusive. Nephrogenic systemic fibrosis (NSF), a disabling disease that can follow gadolinium-based contrast injection during magnetic resonance imaging, is characterized by systemic fibrosis of the skin, joints, liver, heart and vessels. Affected tissues are infiltrated by CD34+ and CD68+ fibroblasts. In the present study, we tested the hypothesis that EPS could have been triggered by a previous gadolinium injection. Methods. We performed histopathological analysis of the peritoneal membrane of two EPS and two control patients all exposed to long-term PD, including immunostaining with CD34 and CD68. The presence of gadolinium and other metals was also assessed by conventional and energy-filtered transmission electron microscopy. Results. Numerous CD34+ and CD68+ cells were found in both the EPS and control patients within the vascular endothelium and in macrophages, respectively, but not in interstitial fibrocytes, as it could be expected in NSF. No trace of gadolinium deposits could be found in the four peritoneal samples; dispersed tiny iron inclusions were evidenced in the connective tissue of both EPS patients. Conclusions. These findings argue against the implication of gadolinium in the development of EPS in long-term PD patients. [ABSTRACT FROM AUTHOR]

The article presents a case study of a 62-year-old woman with the development of a polycystic liver causing abdominal discomfort and dyspepsia due to autosomal dominant polycystic kidney disease (ADPKD). It says that a 100 µgrams (µg) of octreotide was administered to the patient in which vomiting and diarrhea has occurred. It mentions that night blindess or nyctalopia is the inability to see correctly at night.

Presents a letter to the editor commenting on the pharmacokinetic interaction between valproic acid and meropenem.